Accueil・Liste d'Actions・CareDx Inc

CareDx Inc

Fermé

SecteurSoins de santé

46.28 2.16

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

47.06

Chiffres clés
By Trading Economics
Revenu	108M 111M
Ventes	14M 132M
P/E Moyenne du Secteur	22.522 57.002
BPA	0.17
Marge bénéficiaire	83.848
Employés	761
EBITDA	-3.8M 4.3M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+5.36% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	557M 2.4B
Ouverture précédente	44.12
Clôture précédente	46.28

CareDx Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 20:02 UTC

CareDx Inc shares are lower today amid notable volatility. A recent report showed an unexpected drop in U.S. retail sales, impacting broader market sentiment.

12 août 2026, 19:36 UTC

CareDx Inc. shares are lower today, reflecting a slight decline since Tuesday's close, despite earlier rebounding from a session low.

11 août 2026, 23:41 UTC

CareDx Inc shares advanced in after-market trading, reflecting notable gains since Tuesday's close. The stock remains well above its 20-day moving average.

10 août 2026, 23:46 UTC

CareDx Inc shares are higher in after-market hours, trading significantly above their 20-day moving average and near the upper end of their one-month range.

7 août 2026, 20:06 UTC

CareDx Inc shares are higher today, recovering from an early dip. The stock has gained significantly since Thursday amid a decline in Treasury yields.

5 août 2026, 19:46 UTC

Shares of CareDx Inc. are lower today amid unusual volatility, reflecting a broader market sentiment influenced by disappointing employment data from ADP.

4 août 2026, 21:36 UTC

CareDx Inc shares are higher in after-market trading, reflecting a broader U.S. stock rally amid declining crude oil prices easing inflation concerns.

3 août 2026, 20:02 UTC

News

CareDx Inc shares rise following a rating upgrade to Buy from Craig-Hallum and a new price target of $64, up from $35.

31 juil. 2026, 23:06 UTC

News

CareDx shares are lower in after-market hours despite a 52% revenue increase to $132 million and raised full-year guidance to $490 million-$500 million.

30 juil. 2026, 23:41 UTC

News

CareDx Inc reported second-quarter revenue of $132 million, exceeding estimates. Following strong results and raised guidance, shares are higher in after-market trading.

29 juil. 2026, 19:56 UTC

CareDx Inc shares are lower, continuing a six-session decline amid rising crude oil prices and inflation concerns affecting broader market sentiment.

27 juil. 2026, 19:16 UTC

News

CareDx Inc is trading lower today, reflecting broader market trends amid declining oil prices and easing geopolitical tensions ahead of the Federal Reserve meeting.

22 juil. 2026, 19:16 UTC

CareDx Inc shares are lower today with no specific news identified. Broader market sentiment is affected by rising crude oil prices amid geopolitical tensions.

20 juil. 2026, 18:53 UTC

News

CareDx shares are lower as Director Valantine Hannah sold 28,779 shares at prices between $36.14 and $36.55, raising investor concerns.

Comparaison

Variation de prix

CareDx Inc prévision

Objectif de Prix

By TipRanks

5.36% hausse

Prévisions sur 12 Mois

Moyen 47.75 USD 5.36%

Haut 64 USD

Bas 21 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.